chrisvoncsefalvay/vaers-outcomes huggingface dataset:
After vaccination came home couldn't feel hands or feet. They would feel hot and cold and had no feeling in them. Just felt out of it like I received a weird drug. Had the shakes.
The decedent experience nausea, headache, and chest pain approximately 72 hours after receieving her second shot.  She was found deceased later that day.
redness and slight bruise at injection site.  warm to the touch.  began 6 days after 2nd injection.  did not notice until 6th day although not sure if it was there before.  Monitored the area for side effects 2-3 days after the 2nd injection and only small, slight redness at that time. very little soreness immediately after 2nd injection.
Information has been received from a 52 year old female consumer with penicillin and erythromycin allergies and no pertinent medical history who on 14-NOV-2007 was vaccinated (route not reported) in left arm with a "1ml dose" of pneumococcal 23v polysaccharide vaccine (Batch 657042, lot#1345U). Concomitant therapy included influenza virus vaccine (unspecified). On 14-NOV-2007, post vaccination, the patient experienced pain and a burning sensation on the left arm which was the injection site right after receiving the pneumococcal 23v polysaccharide vaccine. The patient reported that the injection site became swollen, up to half the size of an egg and turned purple, then green and later yellow. This lasted for a week or more. The patient reported that she wakes up at night because her arm hurts and the pain now travels up to her neck. Per patient, to date, the swelling is gone but the pain and burning are still there. The patient did not receive medical attention and no diagnostic lab test were performed. At the time of this report the patient had not removed. Additional information has been requested.
10 MIN after injection the patient started to feel flush,  Dizzy, and nauseated.  the patient sat for more than 15 min then went to the rest room. patient felt better and was able to leave the store
Warm antibody autoimmune hemolytic anemia. Patient has a a history of PVCs on atenolol and intermittent dizziness she is noted since contracting Covid 1 year ago.  She had the Covid shot 3 days before this visit and she noted more lightheadedness fatigue and malaise.
began to experience generalized itching approx 30 minutes post vaccination.  Approx 40-60 minutes post vaccination developed hives over arms/legs/trunk.  Was treated with Benadryl 50mg IM - complete resolution of symptoms in 30 minutes.
The afternoon of 07/18/2022 I noticed a mild soreness in my throat. It's the kind of thing that I normally get with a cold and that's what I thought it was. I woke up the next day not feeling much worse. At noon that day, I received notification from a work colleague to inform me that she had COVID-19 and we had been at a wedding together that past weekend. I took an at home COVID-19 test at noon that day and it was immediately positive. I contacted my doctor and described my symptoms and how mild they were. However, I woke up the next morning with a severe sore throat and had developed a cough. Both of those symptoms persisted in a severe capacity from 5pm on 07/20/2022 until 07/22/2022. During that time I couldn't sleep due to the fact that I was coughing so much. My doctor prescribed Paxlovid and a cough medication on 07/20/2022 which did not relieve my cough or allow me to sleep. I was also treating myself with Tylenol and Aspirin alternatively. My temperature fluctuated from 100 to 102 and was worse at night. I would wake up with sweating and chills and a productive cough that was producing dark colored mucus. Around 10PM on Friday night, I realized that I was feeling better and felt as though I was through the worst of it. My symptoms improved progressively each day after that and I was able to return to work at a limited capacity although I was still experiencing some extreme fatigue. I was able to return to work at a normal level yesterday, 08/01/2022. I still have a slight cough and a little scratchiness in my throat but I have tested negative for COVID-19.
Within 48 hours after the vaccine I felt very hot and heat coming out of my body. Then, I lost conscientiousness and passed out. This happens when I am sleeping and wake up. This has happened a few times with the first dose. I also have an issue with my tongue where it has a coating on it. Then I had my second dose of Pfizer on 04/02/2022 and within 24 hours I passed out and lost conscientiousness again. I passed out a few more time and the most recent was 3 weeks ago. When this happens, I cannot function. I also have more of tongue issues with a yellow coating on my tongue. I have random neck movements like jerks and my muscles tightening in the back of my neck. It has flared up my underlying health conditions of lupus, fibromyalgia and neuropathy. I also got COVID-19 on 8/18/2021 and had major issues. I have permanently lost my taste and smell. I have severe brain fog and tongue swelling. I took remdesivir that I feel did help. I feel like the vaccine has slowed my immune system and I get sick easily. I have pain, swelling, and joint issues. I cannot feel some things in my hands and all over my body like my sense of feel is mostly gone.
102 fever by Tuesday at 6pm. body chest, chills, my arm hurt feel my back into my fingers.; body chest, chills, my arm hurt feel my back into my fingers.; body chest, chills, my arm hurt feel my back into my fingers.; body chest, chills, my arm hurt feel my back into my fingers.; body chest, chills, my arm hurt feel my back into my fingers.; body chest, chills, my arm hurt feel my back into my fingers.; The joints of my fingers hurt.; My lymph node in my arm pit is swollen so much I can't lift my arm; My lymph node in my arm pit is swollen so much I can't lift my arm.; The left side of my breast feels like I've been punched.; There's a large knot and heat at the injection site.; There's a large knot and heat at the injection site.; I went to bed Tuesday at 4pm and couldn't get out of bed until Wednesday at 9am.; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Er8734) via an unspecified route of administration in the left arm on 24May2021 at 18:30 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient had no known allergies to medications, food, or other products. The patient received other medication within two weeks of vaccination which included Probiotics. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient experienced 102 (unspecified units) fever by Tuesday, on 25May2021 at 16:00. Body chest, chills, the patients arm hurt felt her back into her fingers. The joints of her fingers hurt. The patients lymph node in her arm pit was swollen so much that she couldn't lift her arm. The patient went to bed Tuesday 25May2021, at 16:00 and couldn't get out of bed until Wednesday, 26May2021 at 09:00. The left side of her breast felt like she had been punched. There was a large knot and heat at the injection site. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. The clinical outcome of the events 102 (unspecified units) fever, body chest, chills, arm hurt felt her back into her fingers, the joints of fingers hurt, lymph node in arm pit was swollen so much that she couldn't lift her arm, couldn't get out of bed until Wednesday, 26May2021 at 09:00, the left side of her breast felt like she had been punched, a large knot and heat at the injection site was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Menquadfi was administered after the excursion, with no reported adverse event; Initial information received on 10-Mar-2023 regarding an unsolicited valid non-serious case received via health professional. Number: 01527753.  This case involves 17 years old female patient to whom MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE [MENQUADFI] was administered after the excursion, with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. This case is linked to cases 2023SA082418, 2023SA082416, 2023SA081681, 2023SA082363, 2023SA082367, 2023SA082373, 2023SA082953 and 2023SA082675.   On 20-Dec-2022, the patient received suspect MENINGOCOCCAL A-C-Y-W135 (T CONJ) vaccine Solution for injection at dose 0.5ml once (lot: U7449AB, expiry date: 23-Sep-2029) via intramuscular route in unknown administration site for immunization after the excursion, with no reported adverse event (poor quality product administered) at same day latency.  Action taken with MENINGOCOCCAL VACCINE (MENQUADFI) was not applicable.  No corrective treatment was received for the event.  At time of reporting, the outcome was Unknown for the event poor quality product administered.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
A healthcare professional reported that an unspecified number of pts experienced site "discomfort", subsequent to Prevnar administration. The reporter considered the event due to the needle, not the vaccine. No further information was available at the time of this report.
This spontaneous report was received from an office manager concerning an unknown number of patients of unknown ages and genders. The patients' medical history, concurrent conditions and concomitant medications were not reported. On unknown dates, the patients were vaccinated with doses of ROTATEQ, (lot # M005733, expiration date: 01-OCT-2017) (lot # M004726, expiration date: 19-OCT-2017) (lot # M034799, expiration date: 01-FEB-2018) (lot # L033545, expiration date: 30-MAY-2017) orally for prophylaxis (dose number were not reported). The doses were stored between 32 to 35 Fahrenheit degrees for 120 hours, and 31 Fahrenheit degrees for 216 hours. There was no previous temperature excursion nor data logger involved. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1705USA004193: US-009507513-1705USA004190: US-009507513-1705USA004191: US-009507513-1705USA004192: US-009507513-1705USA004094.
10 min after injection pt c/o watery eyes, frontal headaches, R eye twitch, R face twitch, nauseous and dizzy
Flushing Rash; eyes stared to swell; fatigued; light head; rash; Turned all red; This spontaneous case was reported by a consumer and describes the occurrence of FLUSHING (Flushing Rash), EYE SWELLING (eyes stared to swell), FATIGUE (fatigued), DIZZINESS (light head) and RASH (rash) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event.    On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FLUSHING (Flushing Rash), EYE SWELLING (eyes stared to swell), FATIGUE (fatigued), DIZZINESS (light head), RASH (rash) and ERYTHEMA (Turned all red). At the time of the report, FLUSHING (Flushing Rash), EYE SWELLING (eyes stared to swell), FATIGUE (fatigued), DIZZINESS (light head), RASH (rash) and ERYTHEMA (Turned all red) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant information provided. Treatment included Benadryl, Pepcid, Prednisone
Approximately 30 minutes after vaccination the patient experienced a cardiac arrest. He was brought to the hospital where resuscitation efforts were continued but ultimately proved to be unsuccessful. The patient was pronounced deceased.
Per triage record documented by provider on site. Patient presenting with complaint of throat itch and anxiety. Provider assessed patient administered single dose epi 0.3mg IM. S/S improved patient sent home.
Like an hour after getting the vaccine one side of her face felt cold. This lasted about three minutes.
Patient presented to facility with shortness of breath and cough. Patient stated symptoms started 9 days prior to admission. patient stated he tested positive prior to admission six days ago. Patient stated he also started Regeneron treatment.
My husband and I had been traveling, I started not feeling well on March 16, 2023. I had severe nasal congestion, chills, never, body aches, I knew it was more than a head hold. I used a home COVID-19 test that had come back positive. I called my doctor to have a telehealth visit, we discussed my symptoms. She prescribed PAXLOVID that I started immediately; I noticed an improvement in my symptoms within a couple of days.
Day after shot in morning  extreme fatigue and burning pain in feet. Stayed in bed all day. I day after shot difficulty walking and pain in right leg, hands and bottom of feet. Continual pain in toes and hands with problem walking.  At times my left leg would not move without extreme pain.  Trouble sleeping due to pain in feet must take pain medicine to sleep. 4 Dec my right toes were unable to move normally almost paralyzed.   6 Dec visited doctor and he believes the problem is neurological.  Will set up physical therapy after holidays.
Information has been received from a lawyer regarding a case in litigation concerning a male patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare provider recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 2014, the patient was administered the ZOSTAVAX (lot number, dosage and route of administration not provided) by a clinic. On or about 2015, the patient was treated at a hospital for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death; aggravation of preexisting conditions and activation of latent conditions (unspecified); lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
vertigo; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a patient (pt) of unknown age and gender. No information was provided regarding the pt's medical history, concurrent conditions, previous drug reactions, allergies and concomitant medications. In or around 2018, the pt was inoculated with zoster vaccine live (ZOSTAVAX) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster) (Strength, dose, route of administration, anatomical location, lot number and expiration date were not reported). On an unspecified date (reported as "Shortly after"), the pt suffered vertigo. As a direct and proximate result of pt's use of zoster vaccine live (ZOSTAVAX), the pt's symptoms had resulted in physical limitations not present prior to using zoster vaccine live (ZOSTAVAX). The pt sustained severe and permanent personal injuries, suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury, and also experienced mental and emotional distress due to resulting physical limitations and seriousness of his condition and suffered incurred damages, including medical expenses; the loss of accumulations; and Other economic and non-economic damages. The outcome of vertigo was not recovered. The event was considered to be related to the suspect vaccine and to be disabling.
Patient received both influenza and pneumococcal vaccines in LD on 11/6. Later that night, patient complained that left arm swelling like a balloon. Patient tried to treat with ibuprofen and ice packs with minimal relief. Patient returned to dr office on 11/8. MD noted left upper extremity as erythematous and swollen. No evidence of lymphedema, edema, ulcerations or lesions. Patient denied shortness of breath, abdominal pain, or chest pain. MD instructed patient to take BENADRYL and ice packs as needed.
Systemic: Dizziness / Lightheadness-Mild, Systemic: Seizure-Mild
ACUTE DVT OF RIGHT FEMORAL VEIN 3/28/2023 CAD (CORONARY ARTERY DISEASE) WO ANGINA ACUTE RESPIRATORY FAILURE 3/28/2023 CAD (CORONARY ARTERY DISEASE) WO ANGINA ACUTE DVT OF RIGHT FEMORAL VEIN 3/28/2023 LEFT OTORRHEA ACUTE RESPIRATORY FAILURE 3/28/2023 LEFT OTORRHEA
Patient currently asymptomatic. No adverse events regarding vaccination administration error. Patient initially received Moderna two-dose series on 1/12/2021 and 2/10/2021 at a different facility. Patient then transferred from that facility whereupon he received Pfizer series on 8/5/2021 and 9/8/2021. Patient then transferred to our facility and received a Moderna booster dose on 3/24/2022. Staff were unaware of the initial Moderna series administered; therefore administered the Moderna booster dose based on the Pfizer series completion dates previously provided.
Pt is a 51F with PMH of asthma, diverticulitis, depression, anxiety, GERD, who presents with lightheadedness and left sided weakness concerning for CVA. However during course noted intermittent confusion episodes that progressed to global confusion, lethargy, somnolence. CTH suspect for encephalitis. MRI- ADEM. LP c/s testing. High dose steroids started x 5 days with plans to try IVIG if no response to steroids. NGT feeds started for nutrition.
Patient complained of acid reflux. I noticed he felt warm.  Took temp. and at this time it is 99.7.
Product storage error; no adverse event; they inadvertently administered 15 doses of the bivalent vaccine which was beyond the 30 use by date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (they inadvertently administered 15 doses of the bivalent vaccine which was beyond the 30 use by date), PRODUCT STORAGE ERROR (Product storage error) and NO ADVERSE EVENT (no adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7168B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 10-Jan-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 10-Jan-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (they inadvertently administered 15 doses of the bivalent vaccine which was beyond the 30 use by date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Product storage error) and NO ADVERSE EVENT (no adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (they inadvertently administered 15 doses of the bivalent vaccine which was beyond the 30 use by date), PRODUCT STORAGE ERROR (Product storage error) and NO ADVERSE EVENT (no adverse event) outcome was unknown. Not Provided      For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (they inadvertently administered 15 doses of the bivalent vaccine which was beyond the 30 use by date) and PRODUCT STORAGE ERROR (Product storage error).    This case contains information for the 4 out of 15 patients as described by the reporter.  No concomitant medication information was provided.  It was reported that that they inadvertently administered 15 doses of the bivalent vaccine which was beyond the 30 use by date. Lot number AS7168B, beyond use date 08Jan2023. Administration dates were as follows: 09-Jan-2023 (2 patients) 10-Jan-2023 (2 patients) 11-Jan-2023 (4 patients) 12-Jan-2023 (4 patients) 13-Jan-2023 (3 patients). All of the patients were 12years and above but HCP did not have the information if some of them were below 17 years old.  No treatment medications were provided.   This case was linked to US-MODERNATX, INC.-MOD-2023-698566.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-698566:Master case
who received the shingrix vaccine 11/14/19 & 1/29/20 / diagnosis in mid February with Shingles; was only 49 at time of vaccine; was only 49 at time of vaccine; This case was reported by a other health professional via call center representative and described the occurrence of shingles in a 49-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On 14th November 2019, the patient received the 1st dose of Shingrix. On 29th January 2020, the patient received the 2nd dose of Shingrix. On 14th November 2019, unknown after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced inappropriate age at vaccine administration. On 29th January 2020, the patient experienced inappropriate age at vaccine administration. In February 2020, the patient experienced shingles. On an unknown date, the outcome of the shingles, inappropriate age at vaccine administration and inappropriate age at vaccine administration were unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional details were provide as follows: A 49 years old patient received two dose of Shingrix, which led to inappropriate age at vaccine administration. In mid of February 2020, the patient was diagnosed with shingles. The insurance did not cover the vaccines due to her age, was only 49 at time of vaccine.  The patient was requesting to be reimbursed for her vaccines.  The reporter wanted to know, did have any recommendations for this patient.
Light fever, stuffiness, runny nose, fatigue. Went away after 36-48 hours